UK markets closed
NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.71 +0.69 (+0.88%) GOLD FUTURES
2,389.90 +30.00 (+1.27%) DOW
39,832.08 +273.97 (+0.69%) Bitcoin GBP
51,672.76 +3,249.09 (+6.71%)
Ensysce Biosciences, Inc. (ENSC)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 02:39PM EDT. Market open.
| Previous close | 0.5564 |
| Open | 0.5400 |
| Bid | 0.4116 x 200 |
| Ask | 0.7220 x 200 |
| Day's range | 0.5400 - 0.6002 |
| 52-week range | 0.5120 - 3.0490 |
| Volume | |
| Avg. volume | 162,191 |
| Market cap | 4.593M |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.6900 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.25 |
Simply Wall St.Ensysce Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Ensysce Biosciences ( NASDAQ:ENSC ) First Quarter 2024 Results Key Financial Results Revenue: US$305.7k (down 61% from...
BenzingaOpioid Developer Ensysce Biosciences Stock Is Shooting Higher Today - Here's Why
Ensysce Biosciences Inc (NASDAQ:ENSC) received an FDA Breakthrough Therapy Designation (BTD) for PF614-MPAR, a next-generation opioid. BTD has been granted to fewer than 300 drugs. It is designed to expedite the development and reviewing of drugs intended to treat a serious condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. PF614-MPAR is designed to provide optimal pain relief at prescribed doses yet limit accid
© 2024 Yahoo. All rights reserved.